Myelin, a multilamellar structure extended from oligodendrocytes or Schwann cells, plays a critical role in maintenance of neuronal function, and damage or loss of myelin causes demyelinating diseases such as multiple sclerosis. For precise alignment of the myelin sheath, there is a requirement for expression of galactosylceramide (GalCer), a major glycosphingolipid in myelin. Synthesis of GalCer is strictly limited in oligodendrocytes in a developmental stage-specific manner. Ceramide galactosyltransferase (CGT), a key enzyme for biosynthesis of GalCer, exhibits restricted expression in oligodendrocytes but the mechanism is poorly understood. Based on our assumption that particular oligodendrocyte-lineagespecific transcription factors regulate CGT expression, we co-expressed a series of candidate transcription factors with the human CGT promoter-driving luciferase expression in oligodendroglioma cells to measure the promoter activity. We found that Nkx2.2 strongly activated the CGT promoter. In addition, we identified a novel repressive DNA element in the first intron of CGT and OLIG2, an oligodendrocyte-specific transcription factor, as a binding protein of this element. Moreover, overexpression of OLIG2 completely canceled the activating effect of Nkx2.2 on CGT promoter activity. Expression of CGT mRNA was also upregulated by Nkx2.2, but this upregulation was cancelled by co-expression of OLIG2 with Nkx2.2. Our study suggests that CGT expression is controlled by balanced expression of the negative modulator OLIG2 and positive regulator Nkx2.2, providing new insights into how expression of GalCer is tightly regulated in cell-type-and stage-specific manners.
Introduction
Glycosylation, the most abundant posttranslational modification of protein, plays key roles for maintaining brain functions such as learning/memory or synaptic plasticity (Kleene and Schachner 2004) , and abnormal regulation of neural glycan expression leads to several neurological disorders (Rutishauser 2008; Muntoni et al. 2011) . Recently, we found that knockout mice for a brainspecific glycosyltransferase, N-acetylglucosaminyltransferase IX (GnT-IX; a branching enzyme for O-mannose glycans), exhibit enhanced myelin recovery after injury in brain (Kanekiyo et al. 2013) , indicating that proper myelin function is maintained by glycosylation.
Myelin is a specialized membrane consisting of oligodendrocytes or Schwann cells, which wraps around neuronal axons and acts as an insulator to maintain neuronal activity. One of the most studied glycosylation changes specific for myelin is the biosynthesis of galactosylceramide (GalCer), the major sphingolipid of the myelin membrane (Jackman et al. 2009 ). GalCer is important for myelin stability, because knockout mice for its biosynthetic enzyme, ceramide galactosyltransferase (CGT), show severe phenotypes such as enlargement of unmyelinated regions and loss of transverse bands between myelinating cells and the axonal membrane (Bosio et al. 1996; Coetzee et al. 1996; Popko 2000) . Moreover, these phenotypes are completely rescued in transgenic mice expressing CGT under the control of an oligodendrocyte-specific promoter (Zoller et al. 2005) . Furthermore, abnormal morphology in the paranodal region of CGT deficient mice is observed in the aged central nervous system (Shepherd et al. 2012) , which is possibly related to poor prognoses of demyelinating diseases such as multiple sclerosis (Bergamaschi 2007) . Although these studies demonstrated that CGT expression is essential for proper myelin function, it remains largely unclear how expression of GalCer and CGT is regulated in oligodendrocytes, leading us to studying their expression mechanisms.
During oligodendrocyte differentiation, GalCer expression starts at the immature oligodendrocyte stage and becomes abundantly expressed together with other myelin proteins, such as 2′-3′-cyclic nucleotide 3′ phosphohydrolase, myelin basic protein, myelin/oligodendrocyte glycoprotein, and proteolipid protein, in oligodendrocytes that enter terminal differentiation (Zhang 2001) . Previous observations of CGT deficiency causing a significant increase in the number of oligodendrocytes indicates that GalCer regulates the final number of oligodendrocytes as well as myelination processes (Marcus et al. 2000) .
Similar to the cell-type-specific expression of GalCer, the CGT gene is highly expressed in oligodendrocytes and Schwann cells, which corresponds to the onset of myelination (Schaeren-Wiemers et al. 1995) , indicating that CGT gene expression is tightly regulated in a spatiotemporal manner. Previous reports have shown that the human CGT promoter includes positive regulatory elements upstream of the transcription start site (Tencomnao et al. 2001) . Subsequently, two cis-elements [a cyclic AMP response element (CRE) and GC-box], and their binding factors (ATF-1 and Sp1/Sp3, respectively) were identified within this regulatory region (Tencomnao et al. 2004) . However, no cell-type-specific factor has been identified, which can explain the mechanism regulating CGT expression in brain oligodendrocytes.
There is limited information on the tissue-specific glycosyltransferase expression pattern. We and others have previously shown that expression of a brain-specific glycosyltransferase, GnT-IX (also designated as GnT-Vb) (Inamori et al. 2003; Kaneko et al. 2003) , and several kinds of ganglioside formation enzymes are under the control of an epigenetic "histone code" (Kizuka et al. 2011; Suzuki et al. 2011) . We have also shown that modification of the neural GnT-IX promoter region with active chromatin marks results in upregulation of GnT-IX transcription by a brain-specific basic-helix-loop-helix (bHLH) factor, NeuroD1 (Kizuka et al. 2011) . Another recent study showed that expression of testis-specific splicing variant of cerebroside sulfotransferase is determined by brother of the regulator of imprinted sites, a testis-restricted transcription regulator (Suzuki et al. 2010) .
In recent years, we have learned much about the transcriptional control that determines neuron-glial fate (Richardson et al. 2006) . Two major groups of transcription factors, bHLH factors (Vetter 2001 ) such as OLIG1, 2 and 3 and homeodomain factors such as Nkx2.2, are mainly involved in the generation and maturation of oligodendrocyte precursor cells (OPCs). In this study, we focused on oligodendrocyte-lineage transcription factors that regulate cell-type-specific CGT expression, and found that CGT expression is regulated by two transcription factors, Nkx2.2 as an activator and OLIG2 as a repressor.
Results

Nkx2.2 enhances CGT promoter activity
A previous study by Tencomnao et al. (2004) showed that the human CGT promoter region (from -554 to -63, corresponding to -747 to -256 in their study; the transcription start site was designated as +1 in this study) contains indispensable regions to govern basic CGT gene expression ( Figure 1A ). However, cell-type-specific factors are yet to be identified for CGT expression in oligodendrocytes. In this study, we presumed that CGT expression would be controlled by oligodendrocyte-specific transcription factors, and we first designed experiments to screen such transcription factors that activate CGT promoter activity. To this end, we cloned a large genomic sequence around the CGT transcription start site from 1.9 kb upstream (-1940 ) to 1.9 kb downstream (+1960). This genomic fragment including exon 1 and a part of intron 1 was ligated to a luciferase reporter plasmid ( Figure 1A ). The resultant CGT promoter-luciferase plasmid (pGV [-1940 /+1960]) was co-transfected with a series of expression vectors carrying candidate transcription factors (OLIG1, OLIG2, OLIG3, Nkx2.2, SOX10 or Id2) into human oligodendrocytic HOG cells (Tencomnao et al. 2001) to measure the luciferase activities. We found that Nkx2.2 markedly increased CGT promoter activity by up to 40-fold compared with that in the control ( Figure 1B ), indicating that Nkx2.2 is a specific activator for CGT transcription.
The above result prompted us to determine the regulatory region that responds to Nkx2.2 within the CGT promoter region. A series of luciferase plasmids with various lengths of the CGT promoter were transfected with or without the Nkx2.2 expression vector into HOG cells. Tencomnao et al. (2004) extensively studied the human CGT 5′-flanking region (from -554 to -63, corresponding to -747 to -256 in the previous study) and identified two important elements, a consensus GC-box (from -74 to -66, corresponding to -267 to -259 in the previous study), known to be recognized by the Sp1 transcription factor, and CRE (from -504 to -497, corresponding to -697 to -690 in the previous study). Therefore, this region was kept in all of the deletion constructs. Neither deletion of the 5′ end from -1940 to -848 nor the 3′ end from +1960 to +1248 had any effect on transactivation of the CGT promoter by Nkx2.2 ( Figure 1C ). By deleting the region from +48 to +18, we found a decrease of the transactivation effect of Nkx2.2 on the CGT promoter, suggesting that this region is responsible for the Nkx2.2-mediated increase of CGT promoter activity. This result prompted us to determine whether Nkx2.2 physically binds to this region. Since Nkx2.2 is expressed at only low levels in HOG cells, we overexpressed Nkx2.2 in these cells, in order to observe the binding of Nkx2.2 to the genomic DNA around the Nkx2.2-responsible region by means of a chromatin immunoprecipitation (ChIP) assay. As a result, we were able to clearly observe the binding of Nkx2.2 to this genomic DNA region ( Figure 1D ). Additionally, we performed database analysis within this region, but it had no sequence homology to the consensus Nkx2.2-binding site (T(C)(T) AAGT(G)(A)(G)(C)TT), raising the possibility that another component binds to this region and enhances CGT promoter activity cooperatively with Nkx2.2.
Characterization of the silencing element in CGT gene intron 1 During analysis of the series of deletion constructs, we unexpectedly found that deletion from +1247 to +610 in CGT intron 1 caused a dramatic enhancement of its promoter activity. This observation suggests the involvement of another transcription factor that binds to this region to repress CGT promoter activity. To determine the DNA region with the silencing ability, we generated a series of mutant constructs with sequential deletion of the corresponding region and then carried out luciferase assays. We determined that the 20 bp region from +819 to +800 was required for the suppression effect ( Figure 2A ). In the database analysis, we found that this region included an E-box (CANNTG), a consensus-binding sequence for bHLH transcription factors (Lee 1997) . Because many neural bHLH transcription factors bind to an E-box to promote or repress target gene expression for cell fate determination in the brain (Ross et al. 2003) , we expected that the E-box element in CGT intron 1 would be critical for repressing transcription. Therefore, we ligated 30 bp double-stranded oligonucleotides from +814 to +785, including the E-box (CATATG) or a mutated E-box (TTTAGA) to the 3′ end of the short promoter construct (pGV[-847/+106]), and then measured the promoter activities. Indeed, ligation of the oligonucleotide containing the original E-box sequence suppressed the promoter activity ( Figure 2B , pGV[-847/+106] + E-box), whereas the mutated E-box did not show the suppression effect ( Figure 2B , pGV [-847/+106] + E-box mu). This result strongly suggests that the E-box in intron 1 is required for transcriptional silencing of the CGT gene. Among several neural bHLH transcription factors, we focused on OLIGs because they are master regulators for oligodendrocyte development and show a transcriptional repression activity (Ross et al. 2003; Ligon et al. 2007 ). To determine which OLIG proteins interact with the E-box, we prepared nuclear proteins from HEK293 cells expressing OLIG1, OLIG2, and OLIG3, and examined their binding to the 30 bp oligonucleotide (from +785 to +814) containing the E-box by electromobility shift assays (EMSAs). For comparison, we also prepared nuclear proteins containing Mash1, another bHLH factor in neuronal progenitors (Cau et al. 1997) . As a result, using HEK293 cells overexpressing OLIG2, we clearly detected an OLIG2-DNA complex, but other bHLH factors, including OLIG1, OLIG3 and Mash1, showed negligible binding to the E-box region ( Figure 2C , left panel). When an unlabeled oligonucleotide (Wt competitor) was added at a 200 M excess to the labeled oligonucleotide, we found inhibition of complex formation, but OLIG2 was still bound to DNA in the presence of the oligonucleotide with the mutated E-box (mu competitor) ( Figure 2C, right panel) . Moreover, the anti-OLIG2 antibody caused a supershift in the OLIG2-DNA complex ( Figure 2D , asterisk). These results indicate that the E-box within intron 1 of the CGT gene is required for binding of OLIG2 to the CGT promoter region.
A previous report showed that the expression of CGT requires CRE and GC-box-binding factors (Tencomnao et al. 2004) . To assess this, we performed EMSA using nuclear extracts from HOG cells expressing Nkx2.2 or OLIG2 to check whether or not the expression of Nkx2.2 and OLIG2 would have an effect on the binding of these factors. The findings indicate that the [-1940 /+1960] vector and pcDNA6 (mock) (n = 3). Data are the means ± SD (*P < 0.05, Student's t-test). (C) Sequential deletion constructs of CGT genomic DNA ligated into a luciferase vector. Each deletion construct was co-transfected with the mock vector or Nkx2.2 expression vector into HOG cells to perform luciferase reporter assays. The luciferase luminescence is shown as described in (B) (n = 3). (D) Binding of Nkx2.2 to the identified genomic region was analyzed by ChIP assay. Chromatin of HOG cells overexpressing Nkx2.2 was immunoprecipitated with anti-Nkx2.2 antibody or normal rabbit IgG. A genomic region (from −23 to +54) including the Nkx2.2-responsive element was quantified in a precipitated DNA by real-time PCR. The values relative to 1% input were shown (n = 4). Data are the means ± SD (*P < 0.05, Student's t-test).
K Okahara et al.
binding of proteins in the CRE or GC-box region was not altered by the expression of Nkx2.2 or OLIG2 (Supplementary data, Figure S1 ). This result suggests that the active effect of Nkx2.2 and the repressive effect of OLIG2 on CGT transcription are independent of CRE and GC-box-binding factors.
Repressive role of OLIG2 in CGT transcription
We found that Nkx2.2 activates the CGT promoter, whereas OLIG2 appears to bind to the repressive E-box within CGT intron 1. Therefore, we expected that OLIG2 expression would repress Nkx2.2-mediated transactivation of the CGT promoter. HOG cells were co-transfected with OLIG2 and Nkx2.2 expression vectors and the CGT promoter-luciferase plasmid pGV [-845/+1247] , and then the promoter activity in these cells was compared with that in cells transfected with the Nkx2.2 expression vector plus the luciferase plasmid. As expected, overexpression of OLIG2 markedly suppressed the activation effect of Nkx2.2 on CGT promoter activity ( Figure 3A ). This result suggests that OLIG2 is a repressing factor for the CGT promoter. Decreasing the ratio of OLIG2 to Nkx2.2 overexpression in HOG cells resulted in gradual elevation of CGT promoter activity ( Figure 3B ), indicating that markedly higher levels of Nkx2.2 to OLIG2 overcome the suppressive effect of OLIG2 on CGT promoter activity.
Nkx2.2 and OLIG2 contribute to the level of endogenous CGT mRNA We then determined whether Nkx2.2 and OLIG2 also contribute similarly to the level of CGT mRNA expression, and found that Nkx2.2 markedly upregulated CGT mRNA expression by >4-fold ( Figure 4A) . Notably, OLIG2 overexpression resulted in remarkable repression of CGT transcriptional activation by Oligonucleotides of the +785 to +814 region with the original E-box (CATATG) or mutated E-box (TTTAGA) were ligated into the 3′ side of the pGV [-847/+106] construct. Then, we measured the promoter activity of each construct in HOG cells. The luciferase luminescence is shown as described in (A) (n = 3). Data are the means ± SD (*P < 0.05, Student's t-test). (C) Binding of bHLH transcription factors (OLIG1, OLIG2, OLIG3 and Mash1) to the probe (+785/+814) was analyzed by EMSAs. Each transcription factor was exogenously expressed in HEK293 cells, and then nuclear extracts were subjected to EMSAs. For the unlabeled competitor, we used an oligonucleotide from +785 to +814 (Wt) or an E-box mutated oligonucleotide (mu). (D) Binding of OLIG2 to the probe (+785/+814) was confirmed by adding anti-OLIG2 antibody. Nuclear proteins from HEK293 cells expressing OLIG2 (OLIG2) were incubated with anti-OLIG2 antibody and subjected to EMSAs. An asterisk shows a super-shifted band.
Nkx2.2 and OLIG2 regulate CGTexpression in oligodendrocytes
Nkx2.2, even though the protein level of Nkx2.2 was not changed by co-expression with OLIG2 ( Figure 4A and B) . However, OLIG2 expression alone had a negligible effect on CGT expression, which may reflect the low level of CGT mRNA in HOG cells. Then, differentiation was induced in HOG cells, as evidenced by an increased expression of Nkx2.2 and CGT mRNAs ( Figure 4C ). By knocking down Nkx2.2 in the differentiated cells by siRNA transfection, we found that expression levels of both Nkx2.2 and CGT were significantly downregulated. Taken together, our results indicate that CGT expression is under coordinated regulation by the repressor OLIG2 and enhancer Nkx2.2.
Nkx2.2 but not OLIG2 is upregulated in mouse brain during development
The results of several recent studies indicate that a subset of OLIG2+ OPCs begin to express Nkx2.2 and develop as myelinating oligodendrocytes (Zhou et al. 2000; Fu et al. 2002; Kucenas et al. 2008) . This suggests that an increased CGT expression would be expected in combination with increased Nkx2.2 expression during the differentiation of oligodendrocytes. To verify this, we measured the mRNA levels of Nkx2.2, OLIG2, CGT, platelet-derived growth factor receptor α (PDGFRα) as a marker for OPC and MBP as a marker for oligodendrocytes using 1-and 2-week-old mouse brains ( Figure 5A ). Compared with a 1-week-old mouse brain, we observed a prominent increase in MBP and CGT mRNAs and a decrease in PDGFRα mRNA in 2-week-old mouse brains, indicating a decrease of OPCs and the appearance of myelinating oligodendrocytes at this stage. It should also be noted that we found a significant increase in Nkx2.2 mRNA, while the level of OLIG2 mRNA remained unchanged, supporting our hypothesis that an increase in the effect of Nkx2.2 on OLIG2 would upregulate CGT expression during neural development.
Discussion
In this study, we showed that oligodendrocyte-lineage transcription factors Nkx2.2 and OLIG2 exert opposing effects on CGT expression. Our observation in which Nkx2.2 upregulated CGT expression, whereas OLIG2 had the ability to cancel the effect of Nkx2.2, has to be interpreted based on the spatiotemporal expression of these transcription factors during neural development. Extensive immunohistochemical analysis using the O1 monoclonal antibody, which specifically recognizes GalCer, during oligodendrocyte development has shown that GalCer is not expressed in oligodendrocyte progenitor cells but it is expressed in immature oligodendrocytes (Bansal et al. 1989 ). In the embryonic central nervous system, emergence of motor neurons and OPCs from ventral regions of the neuroepithelium is induced by sonic hedgehog (Shh), which then disperse throughout the developing gray matter (Miller 1996) . In mice, early expression of OLIG1 and 2, which is regulated by Shh (Lu et al. 2000; Zhou et al. 2000) , plays a causal role in oligodendrocyte-lineage determination because OLIG1/2 is indispensable for the emergence of motor neurons and oligodendrocytes (Takebayashi et al. 2000; Zhou et al. 2002) . At a subsequent stage, Nkx2.2 is upregulated in OLIG2+ differentiating immature oligodendrocytes (Qi et al. 2001; Soula et al. 2001) . Considering the timing and location of Nkx2.2 expression during oligodendrocyte differentiation, our finding that Nkx2.2-enhanced CGT expression by activation of its promoter activity is reasonable. At a later stage, an increasing number of Nkx2.2+ cells start to lose OLIG2 expression during the myelination stage . Based on these observations, our findings that OLIG2 suppressed CGT expression could explain how expression of the myelin component including GalCer is strictly regulated during neural development ( Figure 5B ). CGT expression may be halted until an increase of Nkx2.2 expression overcomes the inhibitory effect exerted by OLIG2. In fact, at a sufficiently high ratio of Nkx2.2 to OLIG2, we observed higher CGT promoter activity.
Even though we identified the cis-element involved in Nkx2.2 binding to the CGT promoter and indeed detected the binding of Nkx2.2 by ChIP assay, this region does not contain the consensus sequence of an Nkx2.2-binding site (Watada et al. 2000) . However, there is increasing evidence demonstrating that Nkx2.2 binds to regions without the consensus-binding motif (Wei et al. 2005; Ji et al. 2011) . A recent report has shown that the epigenetic regulator histone deacetylase-1 is necessary for recruitment of Nkx2.2 to the Sirt2 promoter (Ji et al. 2011) . Here, we found that Nkx2.2 overexpression alone failed to upregulate CGT expression except in oligodendroglia (data not shown). Therefore, our finding does not fully explain the mechanism of GalCer expression and we have to consider the involvement of other regulatory mechanisms such as another transcription factor and epigenetic modulation (Liu et al. 2010; Ji et al. 2011 ).
In conclusion, our finding of the opposing roles of two oligodendrocyte-lineage transcription factors in regulation of restricted CGT expression is an important step toward understanding the myelination process during neural development.
Materials and methods
Cell culture HOG, HeLa, KG-1-C and HEK293 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% Fig. 5 . Expression levels of Nkx2.2 and OLIG2 during mouse brain development. (A) Total RNAs were obtained from 1-and 2-week-old mouse brains. Each gene mRNA, normalized with ribosomal RNA, is shown relative to that in 1-week-old mice (n = 3). Data are the means ± SD (*P < 0.05, Student's t-test). (B) Schematic model of the cell-type-specific expression of CGT regulated by balanced expression of OLIG2 and Nkx2.2. ATF-1 and Sp1/3 were previously identified factors which bind to CGT promoter. During early stage of myelin development in mouse (left), CGT is silenced in OPCs in which OLIG2 (negative regulator for CGT) is expressed. At a subsequent stage (right), Nkx2.2 ( positive regulator for CGT) is upregulated followed by expression of CGT at around postnatal 2 weeks. Balanced expression of these transcription factors might be a switch for CGT expression.
Nkx2.2 and OLIG2 regulate CGTexpression in oligodendrocytes fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin.
Antibodies
The following antibodies were used for western blotting: rabbit anti-Nkx2.2 (Santa Cruz Biotechnology, sc-15015), mouse anti-OLIG2 (Millipore, MABN50) and mouse anti-actin (Sigma, clone AC-40).
Plasmid construction
The human CGT promoter sequence (-1940 to +1960) was cloned by PCR from genomic DNA of HeLa cells using -1940 F and +1960 R primers (Supplementary data, Table S1 ). To generate the pGV [-1940/+1960] construct, the cloned genomic fragment was ligated into the pGV-B2 plasmid (Toyo Ink) using the restriction sites indicated in Supplementary data, Table S1 . For sequential deletion promoter constructs, serial DNA fragments were amplified by PCR from the pGV [-1940 /+1960] construct with the primers indicated in Supplementary data, Table S1 , and then ligated into the pGV-B2 plasmid. To generate pGV[-847/ +106] + E-box and pGV[-847/+106] + E-box mu constructs, pGV[-847/+609] was digested with SmaI followed by eliminating the shorter fragment, and then ligating the larger fragment to synthesized double-stranded oligonucleotides 5′-TCCTGTT TCTCCCATATGGCATCCGTTCGA-3′ or 5′-TCCTGTTTCTC CTTTAGAGCATCCGTTCGA-3′. Each transcription factor cDNA was amplified by PCR from cDNA derived from HEK293 (for Nkx2.2, Mash1, Id2 and SOX10) or KG-1-C (for OLIG1, OLIG2 and OLIG3) cells using the primers listed in Supplementary data, Table S2 . Each cloned DNA fragment was ligated into pcDNA6/myc-His C (Life Technologies) using the restriction sites indicated in Supplementary data, Table S2 .
Luciferase assay
To observe the effects of the transcription factors on CGT promoter activity, HOG cells were triple-transfected with pGV luciferase reporter plasmids containing the CGT promoter region (125 ng), pRL-CMV plasmid (12.5 ng, Toyo Ink) as an internal control reporter, and each transcription factor expression vector (125 ng) using lipofectamine 2000 (Life Technologies) according to the manufacture's protocol. After 24 h, luciferase activity was measured with a PicaGene Dual SeaPansy Luminescence Kit (Toyo Ink) and normalized to the transfection efficiency as measured by Renilla luciferase luminescence derived from pRL-CMV. To determine the silencing sequence, the cells were co-transfected with a series of luciferase plasmids containing various lengths of the CGT promoter sequence (125 ng) and the pRL-CMV plasmid (12.5 ng).
Chromatin immunoprecipitation assay
ChIP was performed as described in "Chromatin Immunoprecipitation (ChIP) Assay" by Kizuka et al. (2011) . Briefly, HOG cells (semi-confluent in 15-cm dishes) overexpressing Nkx2.2 were fixed with 1% formaldehyde in culture media for 10 min, followed by glycine addition (125 mM at final concentration) and 5 min incubation. Chromatin was collected, and ChIP assays were performed using a SimpleChIP Enzymatic Chromatin IP Kit (Cell Signaling Technology) according to the manufacturer's protocol. Before immunoprecipitation, 1% of the chromatin solution was taken as an input sample. The amount of quantified DNAwas shown as a value relative to that of the input sample.
Nuclear protein extraction Nuclear proteins were extracted as described in "Nuclear Protein Extraction" by Kizuka et al. (2011) . The protein concentration of the nuclear extract was measured by a BCA assay (Thermo scientific), and 1 μg of the nuclear proteins was used for EMSAs.
Electromobility shift assay
An oligonucleotide containing the E-box (5′-TCCTGTTTCTC CCATATGGCATCCGTTCGA-3′) was biotinylated with a Biotin 3′-end DNA-labeling kit (Thermo Scientific). As an unlabeled competitor, we used the same oligonucleotide or an E-box mutated oligonucleotide (5′-TCCTGTTTCTCCTTTAGA GCATCCGTTCGA-3′). The biotinylated or unlabeled oligonucleotides and complementary oligonucleotides were mixed in buffer containing 10 mM Tris-HCl, pH 7.5, 0.1 M NaCl and 1 mM EDTA, and then heated at 95°C for 5 min. Then, the solution was cooled gradually to room temperature for annealing. The EMSA was performed with a LightShift Chemiluminescent EMSA kit (Thermo Scientific) according to the manufacture's protocol with a modification (Kizuka et al. 2011) . The competitors were used at a 200 M ratio to the biotinylated oligonucleotides during incubation with the nuclear proteins. For CRE and GC-box regions, we used other oligonucleotides: CRE, (5′-TGGCAAAGGCAGATTCGTCAG-3′) and GC-box, (5′-GA AGAGTGGGCGGGGCCA-3′). These oligonucleotides were biotinyltated and used in the same way as above.
Database analysis
Genomatix (http://www.genomatix.de/, last accessed May 23, 2014) was used to search for putative transcription factor-binding sites.
Cell differentiation and gene knockdown HOG cells (10-cm dish) were cultured in differentiation media [Dulbecco's modified Eagle's medium supplemented with 100 U/ mL penicillin, 100 μg/mL streptomycin, 5 mg/L insulin, 30 nM triiodothyronine (T3), 30 nM sodium selenite, 16.1 mg/L putrescine, 1.25 g/L glucose; de Arriba Zerpa et al. 2000] for 2 days, followed by changing medium to fresh differentiation media. After 1 day, cells were reseeded onto poly-L-lysin-coated 10-cm culture dish, followed by overnight culture. Then, Nkx2.2 siRNA (QIAGEN, SI00659372, 200 pmol for a dish) or control siRNA (QIAGEN, 1027280) was transfected to the cells using lipofectamine 2000 (Life Technologies, 20 μL for a dish) according to the manufacture's protocol. After 48 h, total RNA was collected, and gene expression levels were quantified.
Total RNA extraction and reverse transcription Nkx2.2 or OLIG2 expression vectors (7.5 μg) were transfected into cells (10-cm dish) using lipofectamine 2000, followed by 48 h of culture. Total RNA was extracted from cultured cells using TRI REAGENT (Molecular Research Center). Then, 1 μg total RNA was reverse transcribed using a SuperScript III First-Strand Synthesis System (Life Technologies) with random hexamers.
Real-time PCR Quantitative PCR was performed using an ABI PRISM 7900HT (Life Technologies). We used primers and a TaqMan MGB Probe (Life Technologies) to detect human CGT mRNA and human genomic region (ChIP) (Supplementary table S3) . We used TaqMan Gene Expression Assay probes (Life Technologies) to detect human Nkx2.2 (Hs00159616_m1), mouse CGT (Mm00495930_m1), mouse Nkx2.2 (Mm00839794_m1), mouse OLIG2 (Mm01210556_m1), mouse PDGFRa (Mm00440701_ m1), mouse MBP (Mm01266402_m1) mRNAs. A TaqMan rRNA probe and control primers (Life Technologies) were used for rRNA measurement. The levels of mRNA expression were normalized to the corresponding rRNA levels.
Western blotting
Cells were collected and homogenized in PBS, and the protein concentration of the homogenates was measured by the BCA assay. Protein samples (10 μg) were separated by 5-20% SDS-PAGE with the buffer system of Laemmli (Laemmli 1970) , and then transferred to nitrocellulose membranes. After blocking with 5% skim milk powder in TBS/0.1% Tween 20, the membranes were incubated with primary antibodies and then horse radish peroxidase-conjugated secondary antibodies. Signals were detected with Supersignal West Dura Extended Duration Substrate (Thermo Scientific) using an ImageQuant LAS 4000mini (GE healthcare).
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